Enterprise Value

17.07M

Cash

32.29M

Avg Qtr Burn

N/A

Short % of Float

2.13%

Insider Ownership

36.42%

Institutional Own.

20.04%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Interim Update

EQ101 Details
Celiac disease, Alopecia areata

Phase 2

Data readout

EQ001 (Itolizumab) Details
Ulcerative colitis

Phase 2

Update

Phase 1b

Update

Failed

Discontinued

EQ102 Details
Celiac disease

Failed

Discontinued